|
|
|
23.06.25 - 13:42
|
Standard BioTools Announces Sale Of SomaLogic (AFX)
|
|
|
SAN DIEGO (dpa-AFX) - Standard BioTools (LAB) announced the strategic sale of SomaLogic to Illumina (ILMN), including SomaScan Assay Services, Authorized Sites and KREX for an upfront payment of $......
|
|
|
|
|
|
|
|
|
18.06.25 - 15:06
|
Infinity Bio Closes $8M Series A Financing Led by Illumina Ventures to Expand Leadership in Antibody Reactome Profiling (Business Wire)
|
|
|
Investment supports platform innovation, commercial scaling, and new service development; Infinity acquires the assets of Serimmune, Inc.BALTIMORE--(BUSINESS WIRE)--Infinity Bio, a biotechnology company pioneering technologies to map immune responses at scale, today announced the successful closing of an $8 million Series A financing round. The round was led by Illumina Ventures, with participation from PTX Capital, Blackbird BioVentures, and Propel Baltimore Fund.
As part of the strategic plan to broaden its suite of service offerings, Infinity Bio has acquired the assets of Serimmune, Inc., which was founded in 2014 to provide unbiased antibody reactome services. New MIPSA™ service offerings, including EnviroSIGHT™, are also expected to launch in the second half of 2025.
Infinity Bio will use the proceeds to expand its commercial footprint, accelerate development of its proprietary MIPSA™ platform, and launch new immune profiling services. The platform enables unbiased, high-resolution analysis of...
|
|
|
17.06.25 - 14:06
|
Arima Genomics Appoints Genomics Industry Veteran Tom Willis as Chief Executive Officer and Closes $22 Million Series C Financing (Business Wire)
|
|
|
Illumina Ventures leads round to accelerate Arima's clinical expansionCARLSBAD, Calif.--(BUSINESS WIRE)--Arima Genomics, Inc., a company leveraging whole-genome sequence and structure information to provide comprehensive cancer therapy selection insights, today announced the appointment of Tom Willis, PhD, as chief executive officer and the close of a $22 million Series C financing led by Illumina Ventures. The round includes participation from genomics pioneers John Stuelpnagel and Mostafa Ronaghi, PhD, as well as existing backers Co-Win Ventures and Berkeley Catalyst Fund. The leadership transition and new capital mark a strategic pivot as Arima strengthens its focus on transforming oncology testing.
“During my decade at Illumina Ventures, I evaluated countless genomics innovations, yet Arima's approach stands out for its ability to illuminate aspects of the genome most tests never see,” said Willis. “I'm joining from the inside because I believe Arima is uniquely positioned to help save patien...
|
|
|
|
|
|
|
|
|
02.06.25 - 14:06
|
Lightcast Appoints Industry Veteran Philip Binns as Chairman of the Board (Business Wire)
|
|
|
Former Agilent executive to help guide commercial growth strategies for groundbreaking benchtop single-cell functional analysis platformCAMBRIDGE, England & CAMBRIDGE, Mass.--(BUSINESS WIRE)--#AntibodyDiscovery--Lightcast, a pioneering life science tools company, today announced the appointment of Philip Binns as chairman of its board of directors, effective May 1, 2025. With this appointment, the Lightcast board includes one investor director each from Arch Ventures, Illumina Ventures, M-Ventures, and Longwall Ventures; two independent directors, Kevin Knopp, CEO of 908 Devices, and Kevin Hrusovsky, chairman and former CEO of Quanterix; and observers from OMX Ventures, +ND Capital, and Terra Magnum.
"We are thrilled to add Phil to our highly experienced board," said Paul Loeffen, PhD, CEO of Lightcast. "His extensive industry expertise and proven leadership will be invaluable as we evolve from a product development-focused company into a fully commercial organization, expanding our global ...
|
|
|
|
|
|
|
|
|
|
|
|
|
27.05.25 - 16:18
|
Pillar Biosciences Raises $34.5M in Funding (PR Newswire)
|
|
|
NATICK, Mass., May 27, 2025 /PRNewswire/ -- Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced they have finalized $34.5M in funding, including a strategic investment from Illumina, structured financing from Soleus Capital and investments from existing investors.......
|
|
|
21.05.25 - 04:06
|
What 15 Analyst Ratings Have To Say About Illumina (Benzinga)
|
|
|
Latest Ratings for ILMN
DateFirmActionFromTo Feb 2022Piper SandlerMaintainsOverweight Feb 2022SVB LeerinkMaintainsMarket Perform Jan 2022StifelUpgradesHoldBuy
View More Analyst Ratings for ILMN
View the Latest Analyst Ratings
read more...
|
|
|
|
|
|
|
15.05.25 - 18:18
|
Quantum-Si (QSI) Earnings Coverage: Complete 1Q Coverage (24/7 Wall St.)
|
|
|
Live Updates Live Coverage Updates appear automatically as they are published. QSI Earnings Backdrop 11:26 am Quantum-Si operates at the intersection of biotech instrumentation and proteomics, targeting academic and pharma customers with novel single-molecule protein sequencing tech. The industry has seen strong interest in next-gen diagnostic platforms, but commercial adoption remains slow. Illumina's recent restructuring […]
The post Quantum-Si (QSI) Earnings Coverage: Complete 1Q Coverage appeared first on 24/7 Wall St.....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
